J H Park1, C H Richards2, D C McMillan2, P G Horgan2, C S D Roxburgh2. 1. Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK. Electronic address: james.park@glasgow.ac.uk. 2. Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
Abstract
BACKGROUND: Tumour stroma percentage (TSP) has previously been reported to predict survival in patients with colorectal cancer (CRC); however, whether this is independent of other aspects of the tumour microenvironment is unknown. In the present study, the relationship between TSP, the tumour microenvironment and survival was examined in patients undergoing elective, curative CRC resection. PATIENTS AND METHODS: Patients undergoing resection at a single centre (1997-2008) were identified from a prospective database. TSP was measured at the invasive margin and its association with cancer-specific survival (CSS) and clinicopathological characteristics examined. RESULTS: Three hundred and thirty-one patients were included in the analysis. TSP was associated with CSS in patients with stage I-III disease [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.17-2.92, P = 0.009], independent of age, systemic inflammation, N stage, venous invasion and Klintrup-Mäkinen score. Furthermore, TSP was associated with reduced CSS in patients with node-negative disease (HR 2.14, 95% CI 1.01-4.54, P = 0.048) and those who received adjuvant chemotherapy (HR 2.83, 95% CI 1.23-6.53, P = 0.015), independent of venous invasion and host inflammatory responses. TSP was associated with several adverse pathological characteristics, including advanced T and N stage. Furthermore, TSP was associated with an infiltrative invasive margin and inversely associated with necrosis. CONCLUSIONS: The TSP was a significant predictor of survival in patients undergoing elective, curative CRC resection, independent of adverse pathological characteristics and host inflammatory responses. In addition, TSP was strongly associated with local tumour growth and invasion.
BACKGROUND:Tumour stroma percentage (TSP) has previously been reported to predict survival in patients with colorectal cancer (CRC); however, whether this is independent of other aspects of the tumour microenvironment is unknown. In the present study, the relationship between TSP, the tumour microenvironment and survival was examined in patients undergoing elective, curative CRC resection. PATIENTS AND METHODS: Patients undergoing resection at a single centre (1997-2008) were identified from a prospective database. TSP was measured at the invasive margin and its association with cancer-specific survival (CSS) and clinicopathological characteristics examined. RESULTS: Three hundred and thirty-one patients were included in the analysis. TSP was associated with CSS in patients with stage I-III disease [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.17-2.92, P = 0.009], independent of age, systemic inflammation, N stage, venous invasion and Klintrup-Mäkinen score. Furthermore, TSP was associated with reduced CSS in patients with node-negative disease (HR 2.14, 95% CI 1.01-4.54, P = 0.048) and those who received adjuvant chemotherapy (HR 2.83, 95% CI 1.23-6.53, P = 0.015), independent of venous invasion and host inflammatory responses. TSP was associated with several adverse pathological characteristics, including advanced T and N stage. Furthermore, TSP was associated with an infiltrative invasive margin and inversely associated with necrosis. CONCLUSIONS: The TSP was a significant predictor of survival in patients undergoing elective, curative CRC resection, independent of adverse pathological characteristics and host inflammatory responses. In addition, TSP was strongly associated with local tumour growth and invasion.
Authors: Raymond Oliphant; Gary A Nicholson; Paul G Horgan; Richard G Molloy; Donald C McMillan; David S Morrison Journal: Ann Surg Oncol Date: 2013-03-26 Impact factor: 5.344
Authors: Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid Journal: BMC Cancer Date: 2009-12-11 Impact factor: 4.430
Authors: Alexander B Saltzman; Mei Leng; Bhoomi Bhatt; Purba Singh; Doug W Chan; Lacey Dobrolecki; Hamssika Chandrasekaran; Jong M Choi; Antrix Jain; Sung Y Jung; Michael T Lewis; Matthew J Ellis; Anna Malovannaya Journal: Mol Cell Proteomics Date: 2018-08-09 Impact factor: 5.911
Authors: Stéphanie Zunder; Priscilla van der Wilk; Hans Gelderblom; Tim Dekker; Christoph Mancao; Anna Kiialainen; Hein Putter; Rob Tollenaar; Wilma Mesker Journal: Cell Oncol (Dordr) Date: 2019-05-17 Impact factor: 6.730
Authors: C Unger; N Kramer; D Unterleuthner; M Scherzer; A Burian; A Rudisch; M Stadler; M Schlederer; D Lenhardt; A Riedl; S Walter; A Wernitznig; L Kenner; M Hengstschläger; J Schüler; W Sommergruber; H Dolznig Journal: Oncogene Date: 2017-05-22 Impact factor: 9.867
Authors: Jean A Quinn; Lindsay Bennett; Meera Patel; Mikaela Frixou; James H Park; Antonia Roseweir; Paul G Horgan; Donald C McMillan; Joanne Edwards Journal: Histol Histopathol Date: 2019-10-08 Impact factor: 2.303